Cotrimoxazole Dosing Frequency
Cotrimoxazole is given twice daily (every 12 hours) for most indications.
Standard Dosing Regimens
The FDA-approved dosing and multiple clinical guidelines consistently recommend twice-daily administration for cotrimoxazole (trimethoprim-sulfamethoxazole) across most clinical scenarios 1.
Common Indications - Twice Daily Dosing:
- Urinary tract infections: Every 12 hours for 10-14 days 1
- Acute otitis media (children): Every 12 hours for 10 days 1
- Shigellosis: Every 12 hours for 5 days 1
- Acute exacerbations of chronic bronchitis: Every 12 hours for 14 days 1
- Traveler's diarrhea: Every 12 hours for 5 days 1
- Pertussis treatment/prophylaxis: 2 divided doses for 14 days 2
Pneumocystis jirovecii Pneumonia (PCP):
For treatment of documented PCP, cotrimoxazole requires four times daily dosing (every 6 hours) at higher doses (75-100 mg/kg/day sulfamethoxazole component) for 14-21 days 1.
For prophylaxis against PCP in HIV-infected patients, dosing varies:
- Preferred: One double-strength tablet once daily 3
- Alternative: One double-strength tablet three times weekly on consecutive days 3, 4
Special Populations:
Children: The standard pediatric dosing follows the same twice-daily schedule (every 12 hours) for most infections 5, 4, 1.
Renal impairment: Dosing frequency should be reduced based on creatinine clearance 1:
- CrCl 15-30 mL/min: Half the usual regimen (may extend to once daily)
- CrCl <15 mL/min: Use not recommended
Key Clinical Considerations
The twice-daily dosing schedule balances efficacy with tolerability. While once-daily dosing is used for PCP prophylaxis in specific populations, therapeutic treatment of active infections requires twice-daily administration to maintain adequate serum concentrations 1.
Important caveat: Extended dialysis can substantially remove both trimethoprim and sulfamethoxazole, potentially requiring dose adjustments beyond standard renal dosing recommendations 6. In patients on renal replacement therapy, standard dose reductions may lead to under-dosing.
The combination achieves synergistic antibacterial activity through sequential blockade of folate synthesis, making consistent dosing intervals important for maintaining therapeutic drug levels 7.